FT Options’s Vertex Pharmaceuticals VRTX Stock Holding History

FT Options’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$1.59M	Buy	65,500 +6,500	+11%	+$978K	2.4%	8
2017 Q2	$1.02M	Buy	59,000 +42,000	+247%	+$5.06M	1.76%	16
2017 Q1	$353K	Buy	17,000 +7,500	+79%	+$660K	0.46%	58
2016 Q4	$115K	Buy	+9,500	New	+$773K	0.13%	94

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FT Options's VRTX Position: Q2 2017 in Review

FT Options sold out of Vertex Pharmaceuticals (VRTX) in Q2 2017, closing a stake of 4,582 shares — an estimated $552K sold.

FT Options first reported a position in VRTX in Q3 2016 and held it in 3 quarters. The position peaked at $703K in Q4 2016. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

FT Options reported no remaining Vertex Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
FT Options sold 4,582 Vertex Pharmaceuticals shares in Q2 2017, an estimated $552K.
FT Options first reported a position in Vertex Pharmaceuticals in Q3 2016 and held it in 3 quarters.
FT Options's Vertex Pharmaceuticals position peaked at $703K in Q4 2016.
582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.